Virax Biolabs (VRAX)

• Market cap: $2.09M
• 1 day: -6.43%
• 5 days: -17.61%
• 1 month: -10.88%
• 3 months: -21.79%
• 6 months: -61.47%
• Year to date: -72.71%
• 1 year: -87.06%
• 5 years: -99.94%
• 10 years: -99.94%
• Sector: Healthcare
• Industry: Biotechnology

About: Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Employees: 26